Retrospective Analysis of the Safety and Efficacy of AngioJet Rheolytic Thrombectomy for Acute Pulmonary Embolism: A Single-Center Study

Ann Vasc Surg. 2023 May:92:155-162. doi: 10.1016/j.avsg.2023.01.002. Epub 2023 Jan 19.

Abstract

Background: To investigate the efficacy, safety, and feasibility of AngioJet Rheolytic Thrombectomy (ART) in the treatment of acute pulmonary embolism (APE).

Methods: Twelve patients with intermediate- or high-risk APE received ART and were followed up for 6-32 months. The technical success rate, clinical success rate, mortality, complication, and ancillary and laboratory tests before and after operation were analyzed retrospectively.

Results: The technical and clinical success rates of ART were both 91.67% (11/12). Except for the patient who died of heart failure during the operation, the rest of patients had no serious complications. After operation, arterial oxygen partial pressure increased while hemoglobin and troponin decreased (P < 0.05). All patients were free of recurrence of APE after 6-32 months of follow-up. Pulmonary artery thrombosis significantly reduced or disappeared.

Conclusions: ART is an effective treatment for intermediate- and high-risk APE. It quickly clears the main pulmonary artery thrombus, relieves pulmonary hypertension, and improves the long-term prognosis of patients.

MeSH terms

  • Acute Disease
  • Animals
  • Hominidae*
  • Humans
  • Pulmonary Embolism* / complications
  • Pulmonary Embolism* / diagnostic imaging
  • Pulmonary Embolism* / surgery
  • Retrospective Studies
  • Thrombectomy / adverse effects
  • Treatment Outcome